Biopharmaceutical company GlobeImmune delayed its planned initial public offering without explanation last week, according to news provider MarketWatch.
The Louisville-based firm was looking to raise $60m to $74m in its IPO, which it filed with the SEC in July. The company said earlier this month that it planned to offer 5 million shares between $11 and $13. Wells Fargo and Jefferies were serving as co-lead underwriters.
The firm has raised $115.1m in venture funding.
In January 2010, investment manager Generali Investments was the sole investor in a $17.5m series E venture round. In 2009, the firm raised $10m in a series D round with biopharma firm Celenge International (16.1% pre-IPO stake) as the sole investor.
The firm’s series C was held in 2007, and brought in $41.2m. Wexford Capital (9.4%) led the round, with participation from Celgene, Mellon Family Investment, Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, and WRF Capital. Previous backers also participated.
In 2006, GlobeImmune announced it had raised $38.4m over two tranches through Lilly Ventures (6.5%) and Medica Venture Partners (6.4%) along with Adams Street Partners, Biogen Idec, Genentech, Partners HealthCare, GC&H Investments, Pac-Link, CIDC, and Yasuda Enterprise Development. They were also joined by returning investors.
HealthCare Ventures (14.1%), Morgenthaler Ventures (14.3%), and Sequel Ventures (9.2%) all participated in GlobeImmune’s series A round in 2003; worth $8m.